Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

163.10 +1.92 (+1.19%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

41 42 Next >

Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest ↗

August 24, 2023

Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the...

Via Benzinga

Cheaper Version Of Blockbuster Arthritis Treatment Humira - CVS Health Teams With Sandoz ↗

August 24, 2023

CVS Health Corp (NYSE: CVS) has launched Cordavis, a wholly-owned subsidiary, to work directly with manufacturers to commercialize and/or co-produce biosimilar

Via Benzinga

Could This Medicine Be the Next Winner for Novartis? ↗

August 23, 2023

The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials.

Via The Motley Fool

Gold Rush In Weight Loss Industry Impacts Retailers With Pharmacy Businesses ↗

August 22, 2023

Retailers with pharmacy businesses, including major players like Walmart Inc (NYSE: WMT), Kroger Company (NYSE: KR), and Rite Aid Corp (NYSE:

Via Benzinga

Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis Looms ↗

August 21, 2023

The FDA signed off on Regeneron's high-dose Eylea about two months earlier than expected.

Via Investor's Business Daily

2 Excellent Stocks to Buy and Hold Forever ↗

August 17, 2023

These companies have solid long-term potential.

Via The Motley Fool

2 Top Biotech Stocks to Buy Right Now ↗

August 14, 2023

These drugmakers are among the most dominant in the world.

Via The Motley Fool

Should Income Investors Buy This Blue Chip Stock? ↗

July 23, 2023

This Swiss drugmaker is one of the most dominant players in its industry.

Via The Motley Fool

SpaceX On Par With Intel, Disney; US Weight Loss Drugs Pricier; Moderna, Pfizer's Shot Effective Against New Variant: Today's Top Stories ↗

August 18, 2023

Benzinga

Via Benzinga

Merck Reveals Mixed Results From Pivotal Kidney Cancer Study Of Welireg In Pretreated Patients ↗

August 18, 2023

Merck & Co Inc (NYSE: MRK) released topline results from LITESPARK-005, a Phase 3 trial investigating WELIREG (belzutifan), Merck's oral hypoxia-inducible

Via Benzinga

Novartis' Generic Business Spinoff: Plans Sandoz Spin-Off In Early October, Proposes Share Distribution ↗

August 18, 2023

Novartis AG (NYSE: NVS)

Via Benzinga

3 Unstoppable Dividend Stocks to Buy Right Now ↗

August 12, 2023

These stocks' dividends are more dependable than most.

Via The Motley Fool

Novartis's Remibrutinib Shows Rapid Improvement In Type Of Skin Disorder That Impacts 40M People ↗

August 09, 2023

Novartis AG (NYSE: NVS)

Via Benzinga

Why Novartis Stock Spiked Today ↗

July 18, 2023

A massive share buyback program and an improved outlook powered a mid-single-digit rise in the drugmaker's shares today.

Via The Motley Fool

Novartis Ag (NVS) Q2 2023 Earnings Call Transcript ↗

July 18, 2023

NVS earnings call for the period ending June 30, 2023.

Via The Motley Fool

Novartis Puts Up Its Biggest Earnings Growth In Two Years; Shares Pop ↗

July 18, 2023

Novartis put up more than 17.3% growth in its profit, beating quarterly records since June 2021.

Via Investor's Business Daily

The Year’s Top 3 International ETFs as of August 2023 ↗

August 07, 2023

By investing in international ETFs, you can mitigate potential losses with a more diversified portfolio. Here are three with strong returns.

Via InvestorPlace

3 Biotech Stocks You Better Be Buying on Each and Every Dip ↗

July 27, 2023

Biotech companies can bring about life-changing innovations. We've created a list to help you find the best biotech stocks out there.

Via InvestorPlace

2 Stocks That Raised Their Guidance in July ↗

July 26, 2023

With inflation elevated, these are relatively resilient businesses to invest in.

Via The Motley Fool

Seven Humira Biosimilars: Increased Competition In Arthritis Drug Market Sparks Need For Reform Of Drug Pricing Intermediaries ↗

July 26, 2023

Seven pharmaceutical companies recently launched their biosimilars of AbbVie Inc's (NYSE: ABBV) top-selling

Via Benzinga

The 7 Best Dividend Stocks to Protect Your Portfolio From Global Chaos ↗

July 24, 2023

With global events only rising in entropy, investors ought to consider these best dividend stocks for portfolio protection.

Via InvestorPlace

Week In Review: Novartis In $1 Billion Deal For DTx Pharma ↗

July 22, 2023

Novartis signed a $1 billion agreement to acquire DTx Pharma, a preclinical San-Diego company developing siRNA therapies for neuroscience indications. Meanwhile, Zhuhai Biotheus formed a far-reaching...

Via Talk Markets

Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review ↗

July 21, 2023

But all the major indexes are at or near 15-month highs.

Via Investor's Business Daily

FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt ↗

July 21, 2023

The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in

Via Benzinga

Why Harrow Health Stock Is Trading Higher Today? ↗

July 19, 2023

Harrow Health Inc (NASDAQ: HROW) agreed to acquire the U.S. and Canadian commercial rights for Vevye (cyclosporine ophthalmic solution) 0.1%, a non‑preserved from Novaliq GmbH.

Via Benzinga

Nasdaq Futures Rise As Focus Turns To Tesla, Netflix Q2 Prints: Analyst Says Earnings Need Some 'Heavy Lifting' For Sustained Rally ↗

July 19, 2023

Via Benzinga

NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories ↗

July 18, 2023

Wall Street Journal

Via Benzinga

Novartis Q2 Earnings: Company Lifts Outlook, Launches $15B Share Buyback, Maps Out Sandoz Spin-Off ↗

July 18, 2023

Novartis AG (NYSE: NVS) reported Q2 FY23 sales of $13.62 billion, up 7% Y/Y and 9% on constant currency, beating the consensus

Via Benzinga

Nasdaq, S&P 500 Futures Dip Ahead of Big Bank Earnings, Retail Sales Data: Why This Analyst Stays Cautious About Tech Sector ↗

July 18, 2023

Via Benzinga

Bank of America, Morgan Stanley And 3 Stocks To Watch Heading Into Tuesday ↗

July 18, 2023

With U.S. stock futures trading slightly lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

Headline News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today